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Abstract
Background: Many trials of nebulized therapy have used nebulized saline as a "placebo". However,
nebulized isotonic saline is sometimes used to assist sputum expectoration and relieve
breathlessness in COPD patients. We designed this study to establish if nebulized saline had a
placebo effect or a clinical effect.
Methods: 40 patients were studied following hospital admission for exacerbated COPD (mean
FEV1 30% predicted). Patients were randomised to single-blind administration of either 4 mls of
nebulized isotonic saline using an efficient nebulizer (active group n = 20) or an inefficient nebulizer
(placebo group n = 20). Spirometry and subjective breathlessness scores (Modified Likert Scale)
were measured before nebulized treatment and 10 minutes after treatment.
Results:  There was no significant change in FEV1 after active or placebo nebulized saline
treatment. Patients reported a 4% improvement in mean breathlessness score following placebo
(Wilcoxon test; p = 0.37) compared with 23% improvement following active nebulized saline (p =
0.0001). 65% of patients given active nebulized saline but only 5% of the placebo group reported
that mucus expectoration was easier after the treatment.
Conclusions:  This study lends support to the current use of nebulized saline to relieve
breathlessness (possibly by facilitating sputum clearance) in COPD patients. Lung function was not
affected. Nebulized saline can therefore be used as a placebo in bronchodilator studies involving
COPD patients but it cannot be used as a placebo in trials assessing symptom relief.
Background
Nebulized saline is used by some doctors and physiother-
apists to assist mucus clearance and to relieve breathless-
ness in patients with COPD, bronchiectasis and Cystic
Fibrosis. This practice is justified by a small number of
studies which have demonstrated enhanced sputum
expectoration or improved breathlessness after nebulized
saline or humidified oxygen [1-4]. Nebulized hypertonic
or isotonic saline has been used to obtain induced sputum
specimens from patients with asthma and COPD for diag-
nostic and experimental purposes [5-9]. For example, Vla-
chos-Mayer and colleagues [5] used increasing strengths
of nebulized saline (from isotonic up to 5%) to induce
sputum in 304 patients with asthma and 25 patients with
COPD. Satisfactory specimens were obtained in 93% of
cases, 17% of asthmatic patients and 56% of COPD
patients required only isotonic saline to achieve sputum
induction.
However, nebulized saline has also been used as a placebo
in several trials involving nebulized bronchodilator ther-
apy [10,11]. For example, Jenkins et al [10] found in a
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double blind study that patients reported clinical benefit
from nebulized saline (with MDI bronchodilator therapy)
which was similar to the subjective response to nebulized
bronchodilator therapy given with placebo MDI therapy.
It was assumed that these patients had a placebo response
to nebulized saline but it is also possible that they may
have experienced a non-bronchodilator benefit from neb-
ulized saline. We have designed a trial to determine
whether the symptomatic benefit associated with neb-
ulized saline use in clinical trials is a placebo effect or a
non-bronchodilator therapeutic effect.
Methods
40 patients were studied during a hospital admission for
an exacerbation of COPD. Patients were recruited at a
time when their condition had stabilized prior to their
planned discharge from hospital. Clinical details of the
patients are summarised in table 1. Six patients undertook
both limbs of the study (partial crossover design).
Patients were randomised to receive 4 mls of 0.9% saline
using an efficient nebulizer system (active group) or an
inefficient nebulizer system (placebo group). The active
nebulizer was a System 22 Acorn nebulizer (Medic-Aid,
Bognor Regis UK Ltd) driven by the hospital's piped oxy-
gen supply at a flow rate of 9 l/min for 10 minutes. This
nebulizer system was found to deliver 95% of particles in
the size range 2.5 to 2.8 microns using a Malvern laser sys-
tem. (Measurement courtesy of Dr Steve Newman, Princi-
pal Physicist, Royal Free Hospital, London, UK). This
small particle size was selected to achieve effective deliv-
ery to the airways. The placebo nebulizer was an old
model (1980s) Bard Inspiron nebulizer (no longer manu-
factured) driven by oxygen at a flow rate of 3 l/min. This
nebulizer system delivered 95% of particles in the size
range 9.5 to 9.9 microns. This particle size was selected to
achieve a placebo effect with deposition in the tubing of
the system and in the pharynx but little penetration to the
airways [12]. Both nebulized treatments were adminis-
tered by mouthpiece to avoid nasal deposition of saline
droplets and to make it less likely that patients would
notice that the output from the placebo system was differ-
ent to previous nebulized treatment which they had
received.
The trial was conducted in a single-blind manner. 40 slips
of paper were labelled "Treatment A" or "Treatment B"
and placed in opaque brown envelopes. These were shuf-
fled in random order and each patient was asked to select
one envelope. This was then opened by the investigator
and the appropriate treatment was administered (A active,
B Placebo). For the six patients who took part in the study
twice, the second treatment consisted of whichever treat-
ment they had not received previously.
Patients were told that we wished "to observe the effects
of a nebulized treatment which is not a new or experimen-
tal drug". They were not informed of the exact nature of
the nebulized treatments as this might have led patients to
try to guess if the treatment which they received was a
"placebo". The Ethics Committee agreed that it would not
have been possible to measure a true placebo effect if
patients were made aware that both treatments were
saline (not a bronchodilator) and one of the nebulizers
was deliberately made to run inefficiently.
Patients were recruited on the Respiratory Wards of a Uni-
versity hospital. We recruited patients who had diagnosis
of COPD confirmed by a respiratory consultant (patients
with asthma or bronchiectasis were excluded from the
study). Patients were approached by one of the investiga-
tors whilst in a relatively stable phase prior to discharge
from hospital following an admission for exacerbated
COPD. All testing was undertaken between 12.00 and
16.00, at least four hours after bronchodilator treatment.
Prior to participating in the study, patients gave informed
consent and undertook baseline measurement of FEV1
and FVC using the best of 3 blows on a Microlab 3300
Spirometer (Micro-Medical LTD, Rochester, UK. Peak
Expiratory Flow (PEF) was measured using a Wright's
Peak Flow meter. Each patient also recorded an assess-
ment of their perceived level of breathlessness using a
seven point modified Likert scale (1 = Not breathless, 2 =
Very mild breathlessness, 3 = Mild breathlessness, 4 =
Moderate breathlessness, 5 = Severe breathlessness, 6 =
Very severe breathlessness, 7 = Worst possible
breathlessness).
Ten minutes after completion of nebulized therapy, FEV1,
FVC and PEF measurements and subjective breathlessness
scores were repeated. Patients also recorded a subjective
assessment of benefit using the following modified Likert
scale. (1 = No benefit from this treatment, 2 = Very slight
benefit, 3 = Slight benefit, 4 = Moderate benefit, 5 = Good
benefit,, 6 = Very good benefit, 7 = Best possible benefit).
Table 1: Patient Characteristics
Active group Placebo group
Gender 13 Male, 7 Female 12 Male, 8 Female
Age (Mean, SD) 68.1 +/- 7.2
Range 54–79
67.3 +/- 7.4
Range 58–79
Mean FEV1
95% CI
0.77 Litres
0.65–0.89
0.78 Litres
0.61–0.95
FEV1 as % predicted 
(Mean and SD)
29.9 (10.0) 30.6 (14.8)BMC Pulmonary Medicine 2004, 4:9 http://www.biomedcentral.com/1471-2466/4/9
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Patients then received 4 puffs of salbutamol (400 mcg)
using a Metered Dose Inhaler and 750 ml Volumatic
spacer (Glaxo Smith Kleine UK).
Fifteen minutes later, FEV1, FVC and PFR measurements
and subjective breathlessness scores and symptom relief
scores were repeated.
All data was entered on a SPSS version 9 statistical pack-
age. Mann Whitney U-test was used to compare lung func-
tion tests and symptom relief scores. Wilcoxon Signed
Rank test was used to compare the change in breathless-
ness scores for matched pairs before and after nebulized
saline.
The study was approved by Salford and Trafford Research
Ethics Committee. All patients gave written informed con-
sent to partake in the study and to receive a single dose of
nebulized treatment (in addition to all usual treatment).
Results
34 patients completed the study; patient details are sum-
marised in table 1. 6 patients took part in the study twice
(once in each limb). This allowed 20 treatments with each
nebulizer system to be compared.
The baseline FEV1 of the two treatment groups was well
matched. Both groups had a non-significant fall in FEV1
after nebulized saline therapy and a small rise in FEV1
after 400 mcg salbutamol from MDI-spacer (Table 2).
FVC, and PEF changes (not shown in table) were similar
to FEV1 changes.
The placebo group had a 4% improvement in breathless-
ness after treatment (Wilcoxon p = 0.37) compared with a
23% improvement after active nebulized saline (Wil-
coxon p = 0.0001). This corresponded to a reduction from
4/7 (moderate breathlessness) before treatment to 3/7
(mild breathlessness) after treatment in the active treat-
ment group.
Table 2: Results All results expressed as Medians in top line and Mean (and 95% CI) in second line.
Active group Placebo group P value (Mann Whitney)
FEV1 0.77 0.80 0.84
Pre-treatment 0.77 (0.65–0.89) 0.78 (0.61–0.95)
FEV1 0.75 0.73 0.74
Post nebulized saline 0.73 (0.62–0.84) 0.75 (0.59–0.91)
FEV1 0.80 0.77 0.63
Post salbutamol MDI 0.81 (0.67–0.94) 0.79 (0.62–0.96)
Breathlessness 44 0 . 3 4
Score 1 (Pre-treatment). 3.9 (3.6–4.3) 
(1 = Not breathless, 7 = Worst possible breathlessness)
3.5 (3.0–4.0)
Breathlessness 34
Score 2 (Post nebulized saline) 3.0 (2.6–3.5) 3.3 (2.8–3.9) 0.85
Wilcoxon test Score 1 V Score 2 <0.0001 0.37
Breathlessness 33 0 . 3 5
Score 3 (Post salbutamol MDI) 2.9 (2.5–3.3) 3.0 (2.6–3.5)
Wilcoxon test Score 2 V Score 3 0.43 0.014
Symptom Relief 31 0.0002
Score Post nebulized saline 3.1 (2.7–3.6) 
(1 = No benefit, 7 = Best possible benefit)
1.7 (1.2–2.3)
Symptom Relief 33 0 . 3 7
Score Post salbutamol MDI 3.2 (2.7–3.7) 2.9 (2.4–3.4)BMC Pulmonary Medicine 2004, 4:9 http://www.biomedcentral.com/1471-2466/4/9
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The mean symptom relief score (patient's assessment of
benefit) for the active treatment was 3/7, (slight benefit)
almost identical to the response to 400 mcg salbutamol
from MDI. The placebo group had a score of 2/7(very
slight benefit) after nebulized placebo and 3/7(Slight ben-
efit) after 400 mcg salbutamol from MDI.
15 patients in the active group felt better after nebulized
saline, 5 felt the same and no patient felt worse. Six
patients in the placebo group felt better after nebulized
treatment, 12 felt the same and 2 felt worse (Chi Squared
test p = 0.013).
Patients were asked if the nebulized treatments had any
effect other than relief of breathlessness. 13 patients in the
active group (65%) said that the nebulized treatment
assisted sputum expectoration. Only 1 patient in the pla-
cebo group reported this effect (Difference between
groups: -Fisher exact test, p = 0.0001). No patient reported
any adverse effects from either nebulized treatment.
Discussion
This is the first study which has compared active neb-
ulized saline with placebo nebulized saline. The results
suggest that nebulized saline has non-bronchodilator
therapeutic effects that are possibly explained by airway-
moistening and sputum-inducing effects of nebulized
saline. Sputum volume was not measured in the present
study but two thirds of patients who were given nebulized
saline through an efficient nebulizer system reported that
it helped them to expectorate sputum. This finding is con-
sistent with the results of previous studies which have
shown improved sputum clearance and decreased breath-
lessness following the open administration of nebulized
saline [1,3] The results of the present study may be
explained by airway-moistening and sputum-inducing
effects of nebulized saline, both isotonic and hypertonic
[1-9] The study of Vlachos-Mayer and colleagues [5]
showed that most asthmatic patients required hypertonic
saline to achieve sputum induction but more than half of
COPD patients achieved sputum induction with neb-
ulized isotonic saline (similar to the finding that 65% of
COPD patients in the present study reported enhanced
sputum clearance following nebulized saline).
Previous studies have shown that nebulized saline can
have a bronchoconstrictor effect in some patients which is
greater with hypertonic saline than with isotonic saline
and greater in asthma patients than COPD patients
[5,6,8,9] Nebulized isotonic saline had no significant
effect on FEV1 in the study of Poole et al [3] or in the
present study.
The main strength of the present study is inclusion of a
placebo limb using an inefficient nebulizer system.
Patients in the placebo group believed that they were
receiving a nebulized treatment because a placebo effect
could have been abolished if patients were told that both
treatments involved no active medication and one of the
patients involved an inefficient nebulizer system. This
issue was discussed fully with the ethics committee and
found to be acceptable because the patients did not miss
any of their regular medication and they did not receive
any pharmacological treatment. The use of a mouthpiece
ensured that patients could not see or feel that the output
from the experimental system was different to the neb-
ulized bronchodilator therapy which they had received
during their hospital admission (usually via a facemask).
Furthermore, only 6 patients took part in both limbs of
the study so most patients could not have tried to guess
which treatment was more effective.
The 23% improvement in breathlessness in the active
group was equivalent to the subjective benefit following
400 mcg of salbutamol from MDI-spacer. This improve-
ment in breathlessness occurred without bronchodila-
tion, mirroring the findings of Poole et al [3]. Based on the
patients' observations and the results of previous studies,
we believe that the therapeutic effect of nebulized saline
may be produced by enhanced sputum clearance. A previ-
ous study at this hospital showed a similar subjective
response to nebulized saline (given at 7 am) but the pre-
vious study also reported an improvement in FEV1 and
PEF [13]. Patients in the previous study received neb-
ulized saline on awakening, prior to their first bronchodi-
lator treatment of he day. In these circumstances, it is
likely that the nebulized saline assisted the expectoration
of copious overnight secretions in the airways with some
subsequent improvement in airflow. Patients in the
present study were treated at about mid-day, having had
bronchodilator therapy on awakening. It is therefore not
surprising that the beneficial effects of nebulized saline
were more modest in the present study. However, this
study lends support to the common clinical practice of
allowing patients with COPD to have nebulized saline "as
required" as a supplement to regular nebulized bron-
chodilator therapy. This may assists sputum expectoration
and relieve breathlessness without the side-effects that
would occur if additional beta agonist treatment were
given.
This study is in agreement with previous studies which
have shown no bronchodilator effect (or a small bron-
choconstrictor effect) when nebulized saline is given to
patients with COPD [3]. This justifies the continuing use
of nebulized saline as a placebo treatment in clinical trials
of bronchodilator therapy which measure rise in FEV1 or
PEF as the primary outcome measure.BMC Pulmonary Medicine 2004, 4:9 http://www.biomedcentral.com/1471-2466/4/9
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However, as nebulized saline has non-bronchodilator
therapeutic effects, it cannot be used as an inert placebo
treatment in clinical studies where breathlessness or qual-
ity of life are to be measured. For example, Jenkins et al
concluded that nebulized treatment had a strong placebo
effect because patients expressed a preference for neb-
ulized treatment even though the same bronchodilator
effect could be achieved for most of their patients when
nebulized saline was given with active bronchodilator
therapy from a MDI device [10]. It is likely that many of
these patients experienced a non-bronchodilator thera-
peutic benefit such as enhanced mucus clearance during
nebulized saline therapy. It would be possible to co-
administer nebulized saline with MDI bronchodilator
therapy as an alternative to nebulized bronchodilator
therapy for some patients with COPD who report difficul-
ties with mucus clearance. However, this would be more
inconvenient than nebulized bronchodilator therapy
(and at least as expensive). For future clinical trials it
would be possible to have two control groups, one receiv-
ing nebulized saline using an efficient system and one
group using an inefficient system such as that used in the
present study. This would allow investigators to assess
whether nebulized saline had any therapeutic effect on
their patients and it would also assess the true placebo
response rate.
British and European nebulizer guidelines state that most
patients with airflow obstruction should be treated with
hand-held devices unless they have demonstrated clear
additional benefit from the use of nebulized treatment in
carefully monitored domiciliary studies [12,14]. The
present study supports these recommendations, especially
the provision that some patients may be commenced on
nebulized treatment on the basis of substantial subjective
benefit even if an additional bronchodilator response can-
not be demonstrated. This study also supports the present
practice of many physiotherapists and doctors who use
nebulized isotonic saline to assist sputum clearance for
patients with COPD who have difficulty in expectorating
sputum.
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FVC Forced Vital Capacity
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COPD Chronic Obstructive Pulmonary Disease
MDI Metered dose inhaler
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BROD developed the concept for the study and both
authors designed the study protocol.
SYK recruited patients and performed all study
measurements.
Both authors assisted in analysis of the data and prepara-
tion of the manuscript.
Acknowledgements
The authors would like to thank Dr Steve Newman of the Royal Free Hos-
pital, London, UK for testing the two nebulizer systems used in the trial.
References
1. Sutton PP, Gemmell HG, Innes N, Davidson J, Smith FW, Legge JS,
Friend JA: Use of nebulized saline and nebulized terbutaline as
an adjunct to chest physiotherapy. Thorax 1988, 43:57-60.
2. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Cobertson CF:
Short-term efficacy of ultrasonically nebulized hypertonic
saline in cystic fibrosis. Paediatr Pulmonol 1996, 21:77-83.
3. Poole PJ, Brodie SM, Stewart JM, Black PN: The effects of neb-
ulized isotonic saline and terbutaline on breathlessness in
severe chronic obstructive pulmonary disease (COPD). Aust
NZ J Med 1998, 28:322-326.
4. Conway JH, Fleming JS, Perring S, Holgate ST: Humidification as an
adjunct to chest physiotherapy in aiding tracheo-bronchial
clearance in patients with bronchiectasis.  Respir Med 1992,
86:109-114.
5. Vlachos-Mayer H, Leigh R, Sharon RF, Hussack P, Hargreave FE: Suc-
cess and safety of sputum induction in the clinical setting. Eur
Respir J 2000, 16:997-1000.
6. Rytila PH, Lindqvist AE, Laitinen LA: Safety of sputum induction
in chronic obstructive pulmonary disease. Eur Respir J 2000,
15:1116-1119.
7. Wark AB, Simpson JL, Hensley MJ, Gibson PG: Safety of sputum
induction with isotonic saline in adults with acute severe
asthma. Clin Exp Allergy 2001, 31:1745-1753.
8. Sutherland ER, Pak J, Langmack EL, Silkoff PE, Martin RJ: Safety of
sputum induction in moderate-to-severe chronic obstruc-
tive pulmonary disease. Respiratory Medicine 2002, 96:482-486.
9. Cataldo D, Foidart JM, Lau L, Bartsch P, Djukanovic R, Louis R:
Induced Sputum: Comparison between isotonic and hyper-
tonic saline solutions in patients with asthma.  Chest 2001,
120:1815-1821.
10. Jenkins SC, Heaton RW, Fulton TJ, Moxham J: Comparison of
domiciliary nebulized salbutamol and salbutamol from a
metered dose inhaler in stable chronic airflow limitation.
Chest 1987, 91:804-07.
11. Goldman JM, Teale C, Muers MF: Simplifying the assessment of
patients with chronic airflow limitation for home nebulizer
therapy. Respiratory Medicine 1992, 86:33-38.
12. Boe J, Dennis JH, O'Driscoll BR: European Respiratory Society
Guidelines on the use of nebulizers. European Respiratory Journal
2001, 18:228-242.
13. O'Driscoll BR, Kay EA, Taylor RJ, Bernstein A: Home nebulizers:
can optimal therapy be predicted by laboratory studies? Res-
piratory Medicine 1990, 84:471-477.
14. O'Driscoll BR: Nebulizers for chronic obstructive pulmonary
disease. Thorax 1997, 52(Suppl 2):S49-52.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2466/4/9/prepub